Pentoxifylline and Intermittent Claudication
Authors: JOHN A. SPITTELL
Journal: Annals of Internal Medicine (1985)

Editorials1 January 1985Pentoxifylline and Intermittent ClaudicationJOHN A. SPITTELL JR., M.D.JOHN A. SPITTELL JR., M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-102-1-126 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe Food and Drug Administration has recently approved the use of pentoxifylline, a methylxanthine with vasoactive properties (1), for the symptomatic treatment of intermittent claudication due to chronic occlusive peripheral arterial disease. Pentoxifylline may offer an alternative to arterial surgery or transluminal angioplasty for selected patients with intermittent claudication as well as provide a useful adjunct to the conservative management of patients with symptomatic occlusive arterial disease for whom restoration of pulsatile flow is not indicated or feasible.Clinicians and investigators abroad (where pentoxifylline has been in use since 1972) have been studying for more than 10 years the hemorheology,...References1. POPENDIKERBOKSAYBOLLMAN KIV. Zur Pharmakologie des neuen peripheren Gefazdilators 3,7-dimethyl-1-(5-oxohexyl)-Xanthin. Arzneim-Forsch. 1971;21:1160-71. MedlineGoogle Scholar2. DORMANDYHOARECOLLEYARROWSMITHDORMANDY JEJDT. Clinical, haemodynamic, rheological, and biochemical findings in 126 patients with intermittent claudication. Br Med J. 1973;4:576-81. CrossrefMedlineGoogle Scholar3. MARCEL G. Hemorheological agents. In: SPITTELL JA JR., ed. Pharmacological Approach to the Treatment of Limb Ischemia. Philadelphia: College of Physicians of Philadelphia; 1983;125-40. Google Scholar4. MULLER R. Hemorheology and peripheral vascular diseases: a new therapeutic approach. J Med. 1981;12:209-35. MedlineGoogle Scholar5. STEFANOVICH V. Effect of 3,7-dimethyl-1-(5-oxy-hexyl)xanthine and 1-hexyl-3,7-dimethyl xanthine on cyclic AMP phosphodiesterase of the human umbilical cord vessels. Res Commun Chem Pathol Pharmacol. 1973;5:655-62. MedlineGoogle Scholar6. VAN NEUTENVAN BEEKJANSSEN JJP. The vascular effects of flunarizine as compared with those of other clinically used vasoactive substances. Arzneim-Forsch. 1978;28:2082-7. MedlineGoogle Scholar7. ANGELKORTKIESEWETTER BH. Influence of risk factors and coagulation phenomena on the fluidity of blood in chronic arterial occlusive disease. Scand J Clin Lab Invest [Suppl]. 1981;156:185-8. CrossrefGoogle Scholar8. MATZKYDARIUSSCHROR RHK. The release of prostacyclin (PGI2) by pentoxifylline from human vascular tissue. Arzneimittel-forsch. 1982;32:1315-8. MedlineGoogle Scholar9. PORTERCUTLERLEE JBB. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled doubleblind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J. 1982;104:66-72. CrossrefMedlineGoogle Scholar10. EHRLY A. Measurements of oxygen tension in muscle. In: SPITTELL JA JR, ed. Pharmacological Approach to Treatment of Limb Ischemia. Philadelphia: College of Physicians of Philadelphia; 1983:65-72. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Mayo Medical School Rochester, Minnesota PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByPentoxifylline in the management of metabolic syndrome and chronic hepatitis CPentoxifylline for Renoprotection in Diabetic Nephropathy: the PREDIAN study. Rationale and basal resultsUrinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: Effects of pentoxifylline administrationThe Role of Antiplatelet Agents in Patients with Peripheral Vascular DiseasePeripheral arterial diseaseEffect of pentoxifylline on decreasedin vitro mononuclear leucocyte chemotaxis in vascular and polysystemic autoimmune diseasesPentoxifylline in the Treatment of Vascular Impotence— Case ReportsDiagnosis and management of occlusive peripheral arterial diseasePhysiology and Pharmacology of Cerebral Blood Flow and MetabolismPentoxifylline Does Not Influence Maximum Ultrafiltration Rates and Peritoneal Transport in RatsPentoxifylline and Diabetic NeuropathyKENNETH L. COHEN, M.D., SUSANNE HARRIS, PA-CPentoxifylline and Aplastic AnemiaROBERT D. MASS, M.D., ALAN P. VENOOK, M.D., CHARLES A. LINKER, M.D., ROBERT E. ZIPKIN, M.D.OXIDANT-INDUCED MEMBRANE DAMAGE IN G-6-PD DEFICIENT RED BLOOD CELLS 1 January 1985Volume 102, Issue 1Page: 126-127KeywordsAngioplastyFood and Drug AdministrationMethylxanthineSurgery Issue Published: 1 January 1985 PDF DownloadLoading ...